Pulmatrix, Inc. (PULM)
Market Cap | 11.03M |
Revenue (ttm) | 4.82M |
Net Income (ttm) | -21.85M |
Shares Out | 3.64M |
EPS (ttm) | -6.95 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 12,185 |
Open | 3.03 |
Previous Close | 3.02 |
Day's Range | 2.98 - 3.06 |
52-Week Range | 2.97 - 7.50 |
Beta | 0.89 |
Analysts | Buy |
Price Target | 10.20 (+236.63%) |
Earnings Date | Apr 4, 2023 |
About PULM
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchop... [Read more]
Financial Performance
In 2021, Pulmatrix's revenue was $5.17 million, a decrease of -59.09% compared to the previous year's $12.63 million. Losses were -$23.37 million, 21.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for PULM stock is "Buy." The 12-month stock price forecast is $10.2, which is an increase of 236.63% from the latest price.
News

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
LEXINGTON, Mass. , Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
LEXINGTON, Mass. , Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minute Tmax and Cmax within the targeted therapeutic range for all three doses tested LEXINGTON,...

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022 LEXINGTON,...

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects pharmacokinetic data from the Phase 1 study in Q4 2022 L...

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass. , ...

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
LEXINGTON, Mass. , July 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its...

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceut...

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update
LEXINGTON, Mass. , March 29, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and n...

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results
Pulmatrix Inc (NASDAQ: PULM) announced topline results of its recently completed Phase 1b clinical study of PUR1800 in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800 is a n...

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD
LEXINGTON, Mass. , March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and no...

Pulmatrix Regains Compliance With Nasdaq Listing Requirements
LEXINGTON, Mass., March 17, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non...

PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?
As Pulmatrix executes a reverse stock split, shares of the tiny pharmaceutical company appear to be defying gravity. The post PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
LEXINGTON, Mass., March 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split
LEXINGTON, Mass. , Feb. 24, 2022 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to add...

Pulmatrix Issues Letter to Stockholders
LEXINGTON, Mass., Feb. 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering
LEXINGTON, Mass., Dec. 17, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to add...

Pulmatrix Announces $6.75 Million Registered Direct Offering
LEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to add...

Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue Estimates
Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update
LEXINGTON, Mass., Nov. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...

Pulmatrix Announces Resolution of Contract Dispute with Cipla
LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bet on Rising P/E Investing With These Top 5 Stocks
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Pulmatrix, Inc. (PULM) Reports Q2 Loss, Tops Revenue Estimates
Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of 22.22% and 47.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?